Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials.
Fernandez-Martinez A, Tanioka M, Fan C, Parker J, Hoadley K, Krop I, Cortes J, Llombart Cussac A, Nuciforo P, Galván P, Pascual T, Partridge A, Prat A, Carey L, Perou C. Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials. Journal Of Clinical Oncology 2019, 37: 571-571. DOI: 10.1200/jco.2019.37.15_suppl.571.Peer-Reviewed Original ResearchHER2-E subtypeCALGB 40601Clinical trialsPredictive biomarkersIntrinsic subtypesEvent-free survival analysisHER2-positive breast cancerAnti-HER2 combinationDual HER2 blockadeAnti-HER2 therapyAnti-HER2 treatmentIndependent predictive biomarkerFree survival analysisPre-treatment tumorsERBB2 mRNA levelsHER2 blockadeLuminal signatureNeoadjuvant settingPCR rateIndependent predictorsLuminal ALuminal BSubtype distributionBreast cancerERBB2 mRNA